Emil D. Kakkis Sells 20,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ultragenyx Pharmaceutical Price Performance

RARE stock traded down $0.22 during mid-day trading on Thursday, reaching $55.90. The company had a trading volume of 90,648 shares, compared to its average volume of 799,793. The company has a market capitalization of $5.15 billion, a PE ratio of -6.99 and a beta of 0.56. The firm has a 50 day moving average of $48.27 and a 200 day moving average of $45.90. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $58.73.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.12. The business had revenue of $147.03 million for the quarter, compared to the consensus estimate of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company’s revenue for the quarter was up 35.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.25) EPS. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.24 EPS for the current year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Ultragenyx Pharmaceutical by 513.8% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 507,095 shares of the biopharmaceutical company’s stock worth $23,677,000 after acquiring an additional 424,476 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 13.3% during the fourth quarter. Franklin Resources Inc. now owns 214,738 shares of the biopharmaceutical company’s stock valued at $10,269,000 after purchasing an additional 25,144 shares in the last quarter. Clearbridge Investments LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 0.7% during the first quarter. Clearbridge Investments LLC now owns 2,400,854 shares of the biopharmaceutical company’s stock valued at $112,096,000 after purchasing an additional 17,362 shares in the last quarter. Rafferty Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 21.2% during the fourth quarter. Rafferty Asset Management LLC now owns 221,910 shares of the biopharmaceutical company’s stock valued at $10,612,000 after purchasing an additional 38,859 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Ultragenyx Pharmaceutical by 3.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock valued at $166,632,000 after purchasing an additional 120,175 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RARE has been the topic of several research analyst reports. Barclays decreased their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. The Goldman Sachs Group boosted their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Canaccord Genuity Group restated a “buy” rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Stifel Nicolaus upped their target price on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the company a “buy” rating in a research report on Friday, May 31st. Finally, Bank of America decreased their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating on the stock in a research report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $87.43.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.